Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 26, 2025, titled "Closure of USFDA inspection at Zydus API Unit at Dabhasa, Gujarat".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has informed the stock exchange about the closure of a USFDA inspection at its Active Pharmaceutical Ingredient (API) manufacturing unit located in Dabhasa, Gujarat, as per a press release dated April 26, 2025. The USFDA routinely inspects Indian drug manufacturing facilities to check compliance with good manufacturing practices. The announcement confirms that the inspection at this particular API facility has concluded. The filing does not specify the outcome of the inspection, such as whether any observations (Form 483) were issued or whether the facility received a clean closure.
USFDA inspection closures are routine but closely watched by investors since outcomes affect the company's ability to supply to the US market. Without details on the result, the market reaction depends on whether any compliance issues were flagged during the inspection.